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INTRODUCTION
Most patients with cancer first present with 
symptoms, typically to non-specialists;1,2 
consequently, ongoing initiatives in several 
countries aim to improve diagnostic 
timeliness for these patients.3–6 Promptly 
suspecting the diagnosis in patients with 
rarer cancers who are symptomatic may be 
particularly challenging, given their overall 
rarity and heterogeneous nature. In recent 
years, international initiatives have focused 
attention on the management of rarer 
cancers but improvements in diagnosis are 
also needed.7
A key marker of diagnostic timeliness 
in patients who are symptomatic and 
subsequently diagnosed with cancer is the 
number of consultations they have with 
a GP before a specialist referral is made, 
which is highly correlated with the ‘primary 
care interval’ (time from first presentation 
to referral).8,9 National audit data indicate 
primary care intervals of approximately 
1, 1.5, and 3 months in patients who 
experience 3, 4, and ≥5 or more pre-referral 
consultations.
Describing variation in pre-referral 
consultations between different patient 
groups and cancers can provide insights 
into aetiological mechanisms responsible 
for diagnostic delay, and help inform future 
policies and research.10,11 In some cancers, 
most patients present with symptoms of 
relatively high predictive value; for example, 
in the case of breast cancer this is a lump, or 
in melanoma a visible skin lesion.10 In some 
other cancers, most patients present with 
poorly predictive symptoms; as an example, 
most patients with pancreatic cancer and 
multiple myeloma present with abdominal 
or musculoskeletal pain, respectively.12,13 
Consequently, variation in the proportion 
of patients who experience multiple 
consultations reflects differences in the 
‘symptom signature’ of different cancers.10,11 
Based on these considerations, it has been 
suggested that different cancers can be 
broadly categorised for their diagnostic 
difficulty, based on the respective frequency 
of multiple (≥3) consultations: cancers in 
which ≥30% of patients experience multiple 
consultations are considered ‘harder to 
suspect’, whereas those for which <15% 
of patients have multiple consultations are 
classed as ‘easier to suspect’.10 
As cancer is a heterogeneous disease, 
evidence about the burden of pre-diagnostic 
consultations across the range of common 
and rare cancers is desirable. Nonetheless, 
currently available evidence (chiefly based 
on information from responders to a national 
patient survey in England) excludes patients 
with several rarer cancers.11 Pooling of data 
from different waves of surveys of patients 
with cancer can help to overcome sample 
size limitations for patients with rarer 
cancers. As a result, a study was conducted 
with the principal objective of addressing 
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Background
Some patients with cancer experience multiple 
pre-diagnostic consultations in primary care, 
leading to longer time intervals to specialist 
investigations and diagnosis. Patients with rarer 
cancers are thought to be at higher risk of such 
events, but concrete evidence of this is lacking.
Aim
To examine the frequency and predictors of 
repeat consultations with GPs in patients with 
rarer cancers.
Design and setting
Patient-reported data on pre-referral 
consultations from three English national 
surveys of patients with cancer (2010, 2013, and 
2014), pooled to maximise the sample size of 
rarer cancers.
Method
The authors examined the frequency and crude 
and adjusted odds ratios for ≥3 (versus 1–2) 
pre-referral consultations by age, sex, ethnicity, 
level of deprivation, and cancer diagnosis (38 
diagnosis groups, including 12 rarer cancers 
without prior relevant evidence).
Results
Among 7838 patients with 12 rarer cancers, 
crude proportions of patients with ≥3 pre-
referral consultations ranged from >30.0% 
to 60.0% for patients with small intestine, 
bone sarcoma, liver, gallbladder, cancer of 
unknown primary, soft-tissue sarcoma, and 
ureteric cancer. The range was 15.0–30.0% 
for patients with oropharyngeal, anal, parotid, 
penile, and oral cancer. The overall proportion 
of responders with any cancer who had ≥3 
consultations was 23.4%. Multivariable logistic 
regression indicated concordant patterns, with 
strong evidence for variation between rarer 
cancers (P <0.001).
Conclusion
Patients with rarer cancers experience pre-
referral consultations at frequencies suggestive 
of middle-to-high diagnostic difficulty. The 
findings can guide the development of new 
diagnostic interventions and ‘safety-netting’ 
approaches for symptomatic presentations 
encountered in patients with rarer cancers.
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current evidential gaps about the burden 
of multiple pre-referral consultations in 
patients with rarer cancers.
METHOD
Data from three waves of the National 
Cancer Patient Experience Survey (2010, 
2013, and 2014), which surveyed patients 
treated for cancer in English NHS hospitals 
during sampling periods of 3 months, 
were analysed.14–16 All three surveys were 
commissioned by the UK Department of 
Health and carried out by Quality Health, 
a specialist survey provider, using identical 
sampling methods. Survey questions 
were cognitively validated on samples of 
volunteer patients. 
Patients were sent a survey questionnaire 
by post a few weeks after discharge and 
after vital status checks, with up to two 
reminders sent to non-responders. 
Response rates were 67%, 64%, and 64% 
respectively for the 2010, 2013, and 2014 
surveys. Anonymous data from the surveys, 
as used in this study, are made available 
for research purposes from the UK Data 
Archive. 
There is no universal definition of what 
constitutes a rarer cancer.7 In this article, the 
authors specifically focus on rarer cancers 
without prior published evidence, 10 of 
which have an annual incidence of <4000/
year in England or <1.5% of the annual 
incidence of all malignant neoplasms, 
excluding non-melanoma skin cancer. 
Data from patients with any cancer were 
included to support direct comparisons 
between these patient groups and to better 
contextualise the findings.
Data analysis
Outcome and exposure variables. The 
information used was provided in response 
to the first question in the questionnaire: 
‘Before you were told you needed to go to 
hospital about cancer, how many times did 
you see your GP (family doctor) about the 
health problem caused by cancer?’ Possible 
answers were:
• none — I did not see my GP before going 
to hospital; 
• once; 
• twice; 
• three or four times;
• ≥5 times; and 
• don’t know/can’t say. 
For the analysis, the binary outcome of 
≥3 versus 1 or 2 pre-referral consultations 
were used; patients who responded that 
they had not seen their GP before going to 
hospital or responded with ‘Don’t know/
can’t say’ were excluded. This binary 
categorisation is concordant with how data 
from this survey are reported publicly, and 
reflects the consideration that some second 
appointments are generated by the need to 
review the findings of investigations ordered 
at the first consultation.10,14–17 Exposure 
variables considered were: 
• age; 
• sex;
• deprivation group (an ecological measure 
of socioeconomic status based on 
quintile groups of the Index of Multiple 
Deprivation scores of the lower super 
output area of patients’ residence18); 
• International Classification of Diseases, 
10th edition diagnosis code based on 
hospital records (Table 1); 
• self-assigned Office for National Statistics 
classification of ethnic group (based on 
responses to a survey item19); and 
• survey wave.
Analysis sample derivation. Of 206 591 
responders to all three surveys, the analysis 
sample was restricted a priori to patients 
who indicated (in response to a survey 
question) that they were diagnosed with 
cancer during the year before completing 
the survey (62.4% of the initial responders’ 
sample). This was done to minimise the 
potential of ‘double-counting’ the few 
responders who may have been treated 
during the sampling periods of more than 
one survey. 
Among patients who saw the GP at least 
once, there was complete information on 
How this fits in
Patients subsequently diagnosed with 
rarer cancers are often thought to 
experience multiple pre-referral primary 
care consultations, but evidence for this 
assertion is limited. The frequency and 
predictors of multiple pre-diagnostic 
consultations in over 7800 patients with 12 
rarer cancers were examined. For patients 
with small intestine, bone sarcoma, liver, 
gallbladder, cancer of unknown primary, 
soft-tissue sarcoma, and ureteric cancer, 
crude proportions of patients with ≥3 pre-
diagnostic consultations of >30.0–60.0% 
were observed. The findings support the 
development of decision support tools, new 
diagnostic pathways, and ‘safety-netting’ 
approaches for patients with possible 
symptoms of rarer cancers.
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Table 1. ICD-10 definitions of cancer types used in analysis a 
  ICD-10 code Incident count  
Cancer type ICD-10 code description (2012), England
Oropharyngeal C01, C09, C10 Malignant neoplasms of base of tongue (C01), tonsil (C09), and oropharynx (C10) 2037 
  
Oral C02, C03, C04, C06 Malignant neoplasm of other and unspecified parts of tongue (C02), gum (C03), 2544 
  floor of mouth (C04), and palate (C06) 
Parotid C07, C08 Malignant neoplasm of parotid gland (C07) and other and unspecified major salivary glands (C08) 556 
   
Oesophageal C15 Malignant neoplasm of oesophagus 7243
Stomach C16 Malignant neoplasm of stomach 5637
Small intestine C17 Malignant neoplasm of small intestine 1065
Colon C18 Malignant neoplasm of colon 22 401
Rectal C19, C20 Malignant neoplasm of recto-sigmoid junction (C19) and of rectum (C20) 11 921
Anal C21 Malignant neoplasm of anus and anal canal 1043
Liver C22 Malignant neoplasm of liver and intrahepatic bile ducts 3867
Gallbladder C23 Malignant neoplasm of gallbladder 686
Pancreatic C25 Malignant neoplasm of pancreas 7371
Laryngeal C32 Malignant neoplasm of larynx 1876
Lung C33, C34 Malignant neoplasm of trachea (C33), and  35 903 
  bronchus and lung (C34) 
Bone sarcoma C40, C41 Malignant neoplasm of bone and articular cartilage of limbs (C40) and other and 412 
  unspecified sites (C41) 
Melanoma C43 Malignant melanoma of skin 11 281
Mesothelioma C45 Mesothelioma 2347
Soft-tissue sarcoma C49 Malignant neoplasm of other connective and soft tissue 1521
Breast C50 Malignant neoplasm of breast 42 773
Vulval/vaginal C51, C52 Malignant neoplasm of vulva (C51) and vagina (C52) 1262
Cervical C53 Malignant neoplasm of cervix uteri 1262
Endometrial C54, C55 Malignant neoplasm of corpus uteri (C54), malignant  7192 
  neoplasm of uterus, unspecified (C55) 
Ovarian C56 Malignant neoplasm of ovary 5582
Penile C60 Malignant neoplasm of penis 505
Prostate C61 Malignant neoplasm of prostate 37 136
Testicular C62 Malignant neoplasm of testis 1874
Renal C64 Malignant neoplasm of kidney, except renal pelvis 7366
Ureteric C65, C66 Malignant neoplasm of renal pelvis (C65) and ureter (C66) 1082
Bladder C67 Malignant neoplasm of bladder 9124
Brain C71 Malignant neoplasm of brain 3959
Thyroid C73 Malignant neoplasm of thyroid gland 2595
Cancer of unknown C77, C78, C79, C80 Secondary and unspecified malignant neoplasm of lymph nodes (C77), secondary malignant 7965 
primary  neoplasm of respiratory and digestive organs (C78), secondary malignant neoplasm of other 
  and unspecified sites (C79), and malignant neoplasm, without specification of site (C80)
Hodgkin lymphoma C81 Hodgkin lymphoma 1555
Non-Hodgkin lymphoma C82, C83, C85 Follicular (nodular) non-Hodgkin lymphoma (C82), diffuse non-Hodgkin lymphoma (C83), 10 144 
   other and unspecified types of non-Hodgkin lymphoma (C85) 
Multiple myeloma C90 Multiple myeloma and malignant plasma cell neoplasms 4190
Leukaemia C91, C92, C93, C94, C95 Lymphoid leukaemia (C91), myeloid leukaemia (C92), monocytic leukaemia (C93), other 7354 
  leukaemias of specified cell type (C94), other leukaemias of unspecified cell type (C95) 
Ductal carcinoma in situ  D05 Carcinoma in situ of breast 5517
Other cancers All other codes
aThe number of incident cases in England is also provided as a measure of cancer frequency; bold italics denote rarer cancers without prior relevant evidence.  
ICD =10 = International Classification of Diseases, 10 th edition. 
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age, sex, and cancer diagnosis, but 2.2% 
had missing information on ethnicity or 
deprivation group — these records were 
excluded from subsequent analyses, 
resulting in an analysis sample of 95 582 
patients. Figure 1 outlines the derivation of 
the analysis sample.
Statistical analysis. The crude proportion 
of patients who had ≥3 consultations are 
described by exposure variable category; 
that is, by age group, sex, ethnicity, 
deprivation group, and cancer diagnosis. 
Subsequently, using logistic regression, the 
crude and adjusted (for all above variables) 
odds ratios (ORs) for ≥3 pre-referral 
consultations are reported. Standard errors 
were calculated with a robust estimator. 
Rectal cancer was used as the reference 
category for cancer, as a result of it having 
a large sample size and occurring in both 
sexes. Additionally, crude proportions of 
patients for each individual category of 
number of pre-referral consultations by 
cancer diagnosis are described. All analyses 
were performed using Stata (version 13). 
RESULTS
After exclusions, 95 582 responders were 
included in the analysis, of whom 7838 were 
patients with the following 12 rarer cancers: 
oropharyngeal, oral, parotid, small intestine, 
anal, liver, gallbladder, bone sarcoma, soft-
tissue sarcoma, penile, ureteric, and cancer 
of unknown primary. Overall, 22 387 (23.4%) 
patients had ≥3 consultations.
There was strong evidence for very 
large variation in crude proportions, and 
crude and adjusted ORs of ≥3 pre-referral 
consultations between patients with different 
cancers (P <0.001, Table 2, Figure 2). The 
proportion of patients with ≥3 consultations 
was highest for small intestine (60.1%) and 
multiple myeloma (47.2%), and lowest for 
melanoma (8.3%), ductal carcinoma in situ 
(5.5%), and breast cancer (5.0%). There was 
a notably large — 40-fold — difference in 
the adjusted odds between small intestine 
cancer and breast cancer in terms of 
patients having ≥3 consultations.
There was also substantial variation 
between patients with any of the 12 rarer 
cancers of prime interest to this study 
(P <0.001 for test of variation between 
these 12 cancers). Specifically, patients 
with seven such cancers (small intestine, 
bone sarcoma, liver, gallbladder, cancer 
of unknown primary, soft-tissue sarcoma, 
and ureteric cancer) had proportions of ≥3 
consultations that were >30.0%; whereas 
patients with five other rarer cancers 
(oropharyngeal, anal, parotid, penile, and 
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2010, 2013, and 2014
surveys
206 591 patients
77 631 patients first treated
for the cancer >1 year
before the survey
31 242 patients did not see
a GP
2127 patients with missing
self-reported ethnicity or
deprivation
9 patients with incoherent
sex and cancer type
95 582 patients
95 591 patients
97 718 patients
128 960 patients
Figure 1. Analysis sample derivation flowchart.
oral cancer) had respective proportions 
of between 15% and 30% (Table 2). 
Multivariable analysis indicated concordant 
patterns (Table 2, Figure 2).
Relatedly, although bone and soft-tissue 
sarcomas tend to present with fairly specific 
symptoms (for example, bony or a soft-tissue 
lump), they principally affect teenagers 
and young adults, and are associated with 
relatively high crude proportions of multiple 
consultations.20 In multivariable analysis, 
however, after adjustment for age group 
and other patient characteristics, the odds 
of ≥3 consultations for these two cancers 
are notably reduced, although remaining 
comparatively high (Table 1).
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Table 2. Crude proportions, crude ORs, and adjusted ORs for ≥3 pre-diagnostic GP consultations, by cancer a
 All responders who Responders with ≥3 Crude OR  Adjusted OR  
Patient characteristics saw GP at least once, n consultations, n (%) (95% CI) P-value (95% CI) P-value
Cancer diagnosis
 Small intestine 218 131 (60.1) 5.18 (3.92 to 6.84)  5.09 (3.85 to 6.73)
 Multiple myeloma 2052 969 (47.2) 3.08 (2.77 to 3.42)  3.08 (2.77 to 3.43)
 Pancreatic 1137 485 (42.7) 2.56 (2.24 to 2.92)  2.52 (2.21 to 2.89)
 Liver 451 167 (37.0) 2.02 (1.65 to 2.47)  1.96 (1.60 to 2.40)
 Bone sarcoma 196 81 (41.3) 2.42 (1.81 to 3.24)  1.89 (1.39 to 2.56)
 Brain 474 186 (39.2) 2.22 (1.83 to 2.70)  1.86 (1.53 to 2.26)
 Stomach 1828 623 (34.1) 1.78 (1.58 to 2.00)  1.86 (1.65 to 2.09)
 Hodgkin lymphoma 969 417 (43.0) 2.60 (2.25 to 2.99)  1.79 (1.54 to 2.08)
 Colon 8053 2640 (32.8) 1.68 (1.55 to 1.81)  1.71 (1.58 to 1.85)
 Gallbladder 66 23 (34.8) 1.84 (1.10 to 3.06)  1.70 (1.03 to 2.80)
 Non-Hodgkin lymphoma 5523 1844 (33.4) 1.72 (1.59 to 1.87)  1.65 (1.52 to 1.80)
 Cancer of unknown primary 3537 1189 (33.6) 1.74 (1.59 to 1.91)  1.63 (1.49 to 1.80)
 Ureteric 331 100 (30.2) 1.49 (1.17 to 1.90)  1.63 (1.28 to 2.08)
 Lung 6405 2068 (32.3) 1.64 (1.51 to 1.78)  1.63 (1.50 to 1.77)
 All other 2281 753 (33.0) 1.70 (1.52 to 1.89)  1.60 (1.43 to 1.78)
 Mesothelioma 641 180 (28.1) 1.34 (1.12 to 1.61)  1.49 (1.24 to 1.80)
 Laryngeal 667 198 (29.7) 1.45 (1.22 to 1.73)  1.49 (1.24 to 1.78)
 Soft-tissue sarcoma 508 162 (31.9) 1.61 (1.32 to 1.96)  1.46 (1.19 to 1.78)
 Ovarian 2717 913 (33.6) 1.74 (1.57 to 1.93) <0.0001 1.45 (1.31 to 1.61) <0.0001
 Renal 1436 431 (30.0) 1.48 (1.30 to 1.68)  1.43 (1.26 to 1.63)
 Oropharyngeal 1155 338 (29.3) 1.42 (1.24 to 1.64)  1.30 (1.13 to 1.50)
 Leukaemia 2043 582 (28.5) 1.37 (1.22 to 1.54)  1.29 (1.14 to 1.45)
 Oesophageal 2887 737 (25.5) 1.18 (1.06 to 1.31)  1.23 (1.11 to 1.37)
 Anal 495 133 (26.9) 1.26 (1.03 to 1.56)  1.14 (0.92 to 1.40)
 Penile 174 38 (21.8) 0.96 (0.67 to 1.38)  1.07 (0.74 to 1.53)
 Prostate 8538 1863 (21.8) 0.96 (0.89 to 1.04)  1.06 (0.97 to 1.15)
 Rectal 5616 1265 (22.5) Ref  Ref
 Bladder 6837 1397 (20.4) 0.88 (0.81 to 0.96)  0.99 (0.90 to 1.07)
 Cervical 706 203 (28.8) 1.39 (1.17 to 1.65)  0.95 (0.79 to 1.14)
 Vulval/vaginal 405 95 (23.5) 1.05 (0.83 to 1.34)  0.93 (0.73 to 1.18)
 Parotid 140 32 (22.9) 1.02 (0.68 to 1.52)  0.89 (0.60 to 1.34)
 Thyroid 940 197 (21.0) 0.91 (0.77 to 1.08)  0.63 (0.53 to 0.76)
 Oral 567 94 (16.6) 0.68 (0.54 to 0.86)  0.61 (0.49 to 0.77)
 Endometrial 3255 549 (16.9) 0.70 (0.62 to 0.78)  0.59 (0.53 to 0.66)
 Testicular 665 96 (14.4) 0.58 (0.46 to 0.73)  0.42 (0.33 to 0.53)
 Melanoma 3470 289 (8.3) 0.31 (0.27 to 0.36)  0.29 (0.25 to 0.33)
 Ductal carcinoma in situ 650 36 (5.5) 0.20 (0.14 to 0.28)  0.15 (0.10 to 0.21)
 Breast 17 549 883 (5.0) 0.18 (0.17 to 0.20)  0.13 (0.12 to 0.15)
… continued
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Table 2 continued. Crude proportions, crude ORs, and adjusted ORs for ≥3 pre-diagnostic GP consultations, 
by cancer a
 All responders who Responders with ≥3 Crude OR  Adjusted OR  
Patient characteristics saw GP at least once, n consultations, n (%) (95% CI) P-value (95% CI) P-value
Sex
 Male 45 151 11 613 (25.7) Ref <0.0001 Ref <0.0001
 Female 50 431 10 774 (21.4) 0.78 (0.76 to 0.81)  1.24 (1.19 to 1.29) 
Age group, years
 16–24 536 231 (43.1) 2.40 (2.02 to 2.85)  2.12 (1.75 to 2.56)
 25–34 1754 508 (29.0) 1.29 (1.16 to 1.44)  1.82 (1.61 to 2.06)
 35–44 5277 1046 (19.8) 0.78 (0.73 to 0.84)  1.46 (1.34 to 1.58)
 45–54 13 113 2937 (22.4) 0.91 (0.87 to 0.96)  1.38 (1.31 to 1.46)
 55–64 22 789 5881 (25.8) 1.10 (1.06 to 1.15)  1.18 (1.14 to 1.23)
 65–74 30 517 7327 (24.0) Ref <0.0001 Ref <0.0001
 75–84 18 442 3860 (20.9) 0.84 (0.80 to 0.88)  0.84 (0.81 to 0.88)
 ≥85 3154 597 (18.9) 0.74 (0.67 to 0.81)  0.78 (0.71 to 0.86)
Ethnic group
 White 91 824 21 024 (22.9) Ref  Ref 
 Mixed 456 161 (35.3) 1.84 (1.52 to 2.23)  1.79 (1.44 to 2.23)
 Asianb 1662 611 (36.8) 1.96 (1.77 to 2.17) <0.0001 2.20 (1.96 to 2.46) <0.0001
 Black 1280 483 (37.7) 2.04 (1.82 to 2.29)  2.17 (1.91 to 2.47) 
 Chinese 236 71 (30.1) 1.45 (1.10 to 1.91)  1.30 (0.96 to 1.76)
 Other 124 37 (29.8) 1.43 (0.97 to 2.10)  1.57 (1.02 to 2.43)
Deprivation groupc
 Affluent 22 351 4883 (21.8) Ref  Ref 
 Deprivation group 2 22 644 5127 (22.6) 1.05 (1.00 to 1.09)  1.04 (0.99 to 1.09)
 Deprivation group 3 20 446 4743 (23.2) 1.08 (1.03 to 1.13) <0.0001 1.05 (1.00 to 1.10) <0.0001
 Deprivation group 4 16 868 4117 (24.4) 1.16 (1.10 to 1.21)  1.08 (1.03 to 1.14)
 Deprived 13 273 3517 (26.5) 1.29 (1.23 to 1.36)  1.16 (1.10 to 1.22)
Survey year
 2010 30 498 7211 (23.6) Ref  Ref 
 2013 32 608 7775 (23.8) 1.01 (0.97 to 1.05) 0.0035 1.02 (0.98 to 1.06) 0.0409
 2014 32 476 7401 (22.8) 0.95 (0.92 to 0.99)  0.97 (0.93 to 1.01) 
Total 95 582 22 387 (23.4)    
aThe table is sorted in descending order of adjusted odds ratios. Rarer cancers without prior published evidence are denoted in bold italics. bThe Asian group excludes Chinese, 
which was treated as a separate category in all three surveys. cAs classified by the Index of Multiple Deprivation. OR = odds ratio.
Regarding sociodemographic variation, 
there was evidence of increasing frequency of 
≥3 consultations with increasing deprivation 
(P<0.001): 26.5% versus 21.8% for patients 
in the groups of most and least deprivation 
respectively. As previously described,11 there 
was strong evidence for crude variation 
in pre-referral consultations by sex, age, 
and ethnicity (P<0.001 for all): with males, 
younger patients, and those from a minority 
ethnic group having a higher proportion 
of multiple pre-referral consultations 
(Table 2). Multivariable logistic regression 
analysis indicated concordant patterns of 
variation by patient characteristic, with the 
exception of a reversal of the sex difference 
(Table 2, Figure 3). 
The distribution of the crude proportions 
of all categories of the number of pre-
referral consultation by cancer diagnosis is 
shown in Figure 4 and Table 3. The overall 
pattern of variation by cancer diagnosis 
in respect of the binary measure of ≥3 
consultations is, for the most part, similar to 
the pattern that would have been observed 
if alternative cut-off points (for example, 
≥2 consultations or ≥5 consultations) had 
been used. 
DISCUSSION
Summary
The proportion of pre-referral consultations 
in patients subsequently diagnosed with 
several rarer cancers was particularly high 
(>30.0%) in patients with small intestine, 
bone sarcoma, liver, gallbladder, cancer 
of unknown primary, soft-tissue sarcoma, 
and ureteric cancer. The proportion of 
patients with any one of five rarer cancers 
(oropharyngeal, anal, parotid, penile, and 
oral cancer) who had ≥3 consultations was 
between 15% and 30%. Using a previously 
suggested classification, therefore, all of 
these cancers could be classified as either 
being harder to suspect or belonging to the 
intermediate diagnostic difficulty category.10
Strengths and limitations 
The main strengths of this study are its large 
sample size — enabling the examination of 
data on several rarer cancers with adequate 
precision — and the availability of data on 
patient characteristics, which allowed for 
the estimation of independent predictors 
of variation. 
However, there are also potential 
limitations. Some patients may have 
recalled the number of relevant pre-referral 
consultations inaccurately, although prior 
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Figure 2. Odds ratios for ≥3 GP consultations before 
hospital referral, by cancer type. Central estimates 
for 12 rarer cancers without prior relevant published 
evidence shown in red.
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Figure 3. Odds ratios for ≥3 GP consultations before 
hospital referral, by patient characteristic.  
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evidence indicates that both patients and 
clinicians provide concordant frequencies 
of pre-referral consultations in patients 
with a given cancer.8 Further, the number 
of consultations that patients themselves 
judge relevant to cancer has high face 
validity, which cannot be dismissed. 
Relatedly, there was no information on 
actual circumstances surrounding the 
multiple consultation events, which may 
have included patient preferences for 
delayed referral or investigation, primary 
care-led investigations, and clinically 
justified expectant (‘safety-netting’) 
management, particularly for patients with 
non-specific symptoms.10,17 It is foolhardy 
to consider that multiple consultations 
represent suboptimal management: care 
is likely to have been concordant with good 
clinical practice in most circumstances, and 
multiple consultations represent scientific 
limitations in current medical knowledge, 
along with a lack of available, easy-to-use, 
reliable tests.10 
Data relate to patients with recent hospital 
treatment for cancer (typically 3–6 months 
before survey participation). This sampling 
method, combined with non-response 
and early mortality patterns, results in 
a sample that is different in its cancer 
diagnosis and sociodemographic case mix 
compared with all incident patients with 
cancer in the population.21 As such, the 
reported proportions of ≥3 pre-referral 
consultations are not fully representative 
of incident patients with cancer and it is, 
therefore, recommended that interpretation 
focuses on patterns of relative variation 
between patients with different cancers and 
characteristics, rather than on the exact 
frequency of ≥3 pre-referral consultations 
by variable category.
Comparison with existing literature
The authors know of no previous studies 
that examine the number of pre-referral 
consultations among patients with the 
studied rarer cancers of prior interest. 
However, in respect of patients with bone 
or soft-tissue sarcoma, the findings amplify 
those from a recent study of diagnostic 
pathways in patients with those cancers, 
indicating that most such patients who were 
diagnosed after a GP referral were referred 
to specialists non-urgently and without 
cancer being suspected as a diagnosis.22 
Similarly, in respect of patients with 
cancer of unknown primary, the findings 
complement those of a recent Australian 
study that indicated delayed recognition of 
the importance of presenting symptoms in 
patients with those cancers.23
Previous evidence indicates that repeat 
consultations occur for between one-
fifth and one-quarter of all patients with 
cancer, although this overall proportion 
varies greatly between patients with 
different cancers and characteristics.8,11 
The present study extends prior relevant 
evidence on the frequency of multiple pre-
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Figure 4. Distribution of crude proportions of all 
categories of number of pre-referral consultation, 
by cancer diagnosis. The blue bars represent rarer 
cancers without prior relevant evidence.
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diagnostic consultations to patients with 12 
rarer cancers. Adding to previous evidence 
that indicates a higher risk of multiple 
pre-referral consultations in younger 
patients, those of minority ethnic groups, 
and males, the study presented here 
also identifies significantly higher risks of 
multiple consultations in patients of greater 
deprivation: prior relevant evidence was 
inconclusive due to power limitations.11 
The frequency of multiple pre-diagnostic 
consultations varies greatly by cancer, 
being greatest for cancers that often 
present with symptoms that are common 
among patients consulting in primary care; 
consequently, these have low predictive 
value for cancer.10 For example, ≥3 pre-
referral consultations occur in between 
one-third and one-half of all patients who 
are subsequently diagnosed with multiple 
myeloma or pancreatic cancer,8,11 which 
commonly present with musculoskeletal 
and abdominal pain, respectively, both 
of which are very common reasons for 
primary care consultations.12,13 
This prior evidence provides insights into 
likely reasons for variation in the frequency 
of ≥3 pre-referral consultations in patients 
with rarer cancers: although some 
patients with small intestine, liver, and 
gallbladder cancers will present with ‘red-
flag’ symptoms that have a relatively high 
predictive value, many will have symptoms 
such as diarrhoea or abdominal pain, which 
have relatively low predictive values for 
these (or other) cancers.24 Similarly, cancer 
of unknown primary typically presents 
with non-specific symptoms. Conversely, 
patients with oral and parotid cancer 
typically present with visible and/or palpable 
lesions (oral ulceration or facial lump) and, 
relatedly, have the lowest proportions of 
multiple consultations among the 12 rarer 
cancers described in this article. Therefore, 
concordant with prior evidence, the findings 
suggest that the frequency of multiple pre-
referral consultations for different cancers 
reflects their ‘symptom signature’ (that 
is, the relative frequency and predictive 
value of the most common presenting 
symptoms); this observation holds true for 
both common and rarer cancers. Further, 
for a given cancer, the frequency of pre-
referral consultations can be considered to 
denote its average diagnostic difficulty at 
first presentation to primary care. 
Two further considerations can help to 
ascertain why the rarer cancers studied 
tend to fall within average or high diagnostic 
difficulty categories:10 
• as rarer cancers are, by definition, very 
infrequent, doctors are particularly 
unfamiliar with their symptomatic 
presentations; and
• specifically for certain rarer cancers, 
greater incidence in younger age groups 
may exacerbate diagnostic difficulties 
as the predictive value of symptoms is 
Table 3. Patients by cancer diagnosis and number of pre-diagnostic GP 
consultations a
 Consultations before referral n (%)
 n 1 2 3–4 ≥5
Small intestine 218 50 (22.9) 37 (17.0) 60 (27.5) 71 (32.6)
Multiple myeloma 2052 632 (30.8) 451 (22.0) 584 (28.5) 385 (18.8)
Pancreatic 1137 374 (32.9) 278 (24.5) 277 (24.4) 208 (18.3)
Liver 451 177 (39.2) 107 (23.7) 105 (23.3) 62 (13.7)
Bone sarcoma 196 75 (38.3) 40 (20.4) 52 (26.5) 29 (14.8)
Brain 474 193 (40.7) 95 (20.0) 107 (22.6) 79 (16.7)
Stomach 1828 746 (40.8) 459 (25.1) 394 (21.6) 229 (12.5)
Hodgkin lymphoma 969 314 (32.4) 238 (24.6) 239 (24.7) 178 (18.4)
Colon 8053 3424 (42.5) 1989 (24.7) 1713 (21.3) 927 (11.5)
Gallbladder 66 27 (40.9) 16 (24.2) 15 (22.7) 8 (12.1)
Non-Hodgkin lymphoma 5523 2372 (42.9) 1307 (23.7) 1187 (21.5) 657 (11.9)
Cancer of unknown primary 3537 1585 (44.8) 763 (21.6) 733 (20.7) 456 (12.9)
Ureteric 331 151 (45.6) 80 (24.2) 69 (20.8) 31 (9.4)
Lung 6405 2628 (41.0) 1709 (26.7) 1301 (20.3) 767 (12.0)
All other 2281 979 (42.9) 549 (24.1) 465 (20.4) 288 (12.6)
Mesothelioma 641 268 (41.8) 193 (30.1) 130 (20.3) 50 (7.8)
Laryngeal 667 303 (45.4) 166 (24.9) 133 (19.9) 65 (9.7)
Soft-tissue sarcoma 508 218 (42.9) 128 (25.2) 109 (21.5) 53 (10.4)
Ovarian 2717 1157 (42.6) 647 (23.8) 588 (21.6) 325 (12.0)
Renal 1436 673 (46.9) 332 (23.1) 273 (19.0) 158 (11.0)
Oropharyngeal 1155 517 (44.8) 300 (26.0) 250 (21.6) 88 (7.6)
Leukaemia 2043 1016 (49.7) 445 (21.8) 373 (18.3) 209 (10.2)
Oesophageal 2887 1437 (49.8) 713 (24.7) 539 (18.7) 198 (6.9)
Anal 495 252 (50.9) 110 (22.2) 85 (17.2) 48 (9.7)
Penile 174 94 (54.0) 42 (24.1) 29 (16.7) 9 (5.2)
Prostate 8538 4045 (47.4) 2630 (30.8) 1329 (15.6) 534 (6.3)
Rectum 5616 3094 (55.1) 1257 (22.4) 888 (15.8) 377 (6.7)
Bladder 6837 3961 (57.9) 1479 (21.6) 974 (14.2) 423 (6.2)
Cervical 706 372 (52.7) 131 (18.6) 115 (16.3) 88 (12.5)
Vulval/vaginal 405 235 (58.0) 75 (18.5) 59 (14.6) 36 (8.9)
Parotid 140 71 (50.7) 37 (26.4) 22 (15.7) 10 (7.1)
Thyroid 940 532 (56.6) 211 (22.4) 133 (14.1) 64 (6.8)
Oral 567 330 (58.2) 143 (25.2) 71 (12.5) 23 (4.1)
Endometrial 3255 2145 (65.9) 561 (17.2) 365 (11.2) 184 (5.7)
Testicular 665 437 (65.7) 132 (19.8) 77 (11.6) 19 (2.9)
Melanoma 3470 2576 (74.2) 605 (17.4) 233 (6.7) 56 (1.6)
Ductal carcinoma in situ 650 535 (82.3) 79 (12.2) 32 (4.9) 4 (0.6)
Breast 17 549 14 988 (85.4) 1678 (9.6) 639 (3.6) 244 (1.4)
aCancer diagnoses are ordered as they appear in Table 2; rarer cancers without prior published evidence are 
denoted in bold italics.
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particularly low compared with the same 
symptom in adults.
Implications for research and practice
The findings underpin the need for 
the development, evaluation, and 
implementation of effective interventions 
aimed at decreasing the average number 
of pre-referral consultations in patients with 
cancer. In recent years, such interventions 
encompassed clinical practice guidelines 
for suspected cancer in primary care, the 
development and introduction of decision 
support tools during the consultation, and 
widening access to specialist investigations, 
such as imaging and endoscopy.24–27 Until 
recently, most interventions aimed at 
decreasing diagnostic intervals have focused 
on patients with relatively common cancers, 
such as initiatives aiming to increase 
endoscopic or imaging investigations for 
patients with suspected colorectal, lung, or 
ovarian cancer.28
Indeed, increased emphasis is being paid 
on system-wide approaches for supporting 
the diagnostic process. For example, ‘one-
stop shop’ multispecialist diagnostic services 
for patients with serious, but unexplained, 
symptoms are being implemented in 
Denmark and the UK. Further, revised 
clinical guidelines for the referral of patients 
with suspected cancer have recently been 
introduced in England, encompassing a 
wide range of presenting symptoms for 34 
different cancers in adulthood, including all 
cancers included in our study.24 Both the 
introduction of one-stop shop, diagnostic, 
clinic models and the implementation of new 
clinical guidelines encompassing a wider 
range of symptomatic presentations are 
likely to help improve diagnostic timeliness 
for patients with rarer cancers. In the 
longer term, the development of biomarker-
enabled, point-of-care diagnostic tests is 
likely to be the most effective intervention for 
reducing multiple pre-referral consultations, 
particularly for cancers with a high level 
of diagnostic difficulty; and, therefore, for 
several rarer cancers.10
In spite of such developments, 
breakthroughs in diagnostic technologies 
are unlikely in the short term, and evidence 
on interventions such as decision support 
tools and new diagnostic care pathways is 
still in emergence. Safety netting patients 
with non-specific symptoms can have a 
role in improving diagnosis in the interim.29 
The 2015 guidelines from the National 
Institute for Health and Care Excellence 
for the referral of patients with suspected 
cancer recommend the review for people 
with symptoms associated with increased 
risk of cancer who do not meet the criteria 
for referral or investigative action. The 
guidelines also encourage patient-initiated 
follow-up visits or arranging planned follow-
up consultations in the presence of recurring, 
persistent, or worsening symptoms.24
These recommendations build on 
previous guidance from the  Royal College 
of General Practitioners on safety netting.30 
It should be noted that safety-netting 
approaches, by their nature, are likely to 
increase the number of consultations before 
referral or investigative actions in some 
patients; however, they can also shorten 
between-consultation intervals and improve 
the patient experience of the diagnostic 
process. Robust evaluation of safety-netting 
is nonetheless required, particularly as 
there is currently a plethora of definitions 
and variable practice. If effective, safety-
netting approaches could be of particular 
benefit for patients subsequently diagnosed 
with rarer cancers.
This study has described the burden of 
pre-diagnostic consultations in primary care 
for patients with a range of rarer cancers. 
As implied by the respective proportions of 
patients having ≥3 consultations, most such 
cancers appear to have at least average, 
and often higher-than-average, diagnostic 
difficulty. The findings presented here 
could guide research and policy initiatives 
to increase diagnostic timeliness for 
patients with rarer cancers, including the 
introduction of decision support tools that 
encompass common relevant symptomatic 
presentations, the development of easily 
accessible multidisciplinary diagnostic 
services, and the wider introduction and 
evaluation of safety-netting approaches.
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